Following Robert Baumgartner’s last TECH Buy transaction on August 28, 2018, the stock climbed by 8.3%. This recent transaction increases Robert Baumgartner’s holding in the company by 6.08% to a total of $1.71 million.
Based on Bio-Techne Corporation’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $192 million and quarterly net profit of $16.46 million. In comparison, last year the company earned revenue of $180 million and had a net profit of $40.86 million. TECH’s market cap is $7.41B and the company has a P/E ratio of 79.26. Currently, Bio-Techne Corporation has an average volume of 97.97K.
Starting in February 2019, TECH received 4 Buy ratings in a row.
The insider sentiment on Bio-Techne Corporation has been negative according to 20 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate.